Literature DB >> 23886137

Roles of fibroblast growth factor-inducible 14 in hepatocellular carcinoma.

Nan Li1, Wen-Jun Hu, Jie Shi, Jie Xue, Wei-Xing Guo, Yang Zhang, Dong-Xian Guan, Shu-Peng Liu, Yu-Qiang Cheng, Meng-Chao Wu, Dong Xie, Shan-Rong Liu, Shu-Qun Cheng.   

Abstract

The prognostic value of the fibroblast growth factor-inducible 14 (Fn14) expression in hepatocellular carcinoma (HCC) is unknown. Real-time PCR (RT-PCR), western blot assays and immunohistochemistry analysis were here performed in order to compare Fn14 expressions in paired liver samples of HCC and normal liver tissue. Most of the tumor tissues expressed significantly higher levels of Fn14 compared to adjacent non-tumor tissues, with Fn14High accounting for 54.6% (142/260) of all patients. The Pearson χ(2) test indicated that Fn14 expression was closely associated with serum alpha fetal protein (AFP) (P=0.002) and tumor number (p=0.019). Univariate and multivariate analyses revealed that along with tumor diameter and portal vein tumor thrombosis (PVTT ) type, Fn14 was an independent prognostic factor for both overall survival (OS) (HR=1.398, p=0.008) and recurrence (HR=1.541, p=0.001) rates. Fn14 overexpression HCC correlated with poor surgical outcome, and this molecule may be a candidate biomarker for prognosis as well as a target for therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23886137     DOI: 10.7314/apjcp.2013.14.6.3509

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  4 in total

1.  Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC.

Authors:  Hong Zhou; Khalid A Mohamedali; Ana Maria Gonzalez-Angulo; Yu Cao; Mary Migliorini; Lawrence H Cheung; Janine LoBello; Xiudong Lei; Yuan Qi; Walter N Hittelman; Jeffrey A Winkles; Nhan L Tran; Michael G Rosenblum
Journal:  Mol Cancer Ther       Date:  2014-09-19       Impact factor: 6.261

2.  TWEAK/Fn14 Axis-Targeted Therapeutics: Moving Basic Science Discoveries to the Clinic.

Authors:  Emily Cheng; Cheryl L Armstrong; Rebeca Galisteo; Jeffrey A Winkles
Journal:  Front Immunol       Date:  2013-12-23       Impact factor: 7.561

3.  Knockdown of the differentially expressed gene TNFRSF12A inhibits hepatocellular carcinoma cell proliferation and migration in vitro.

Authors:  Tao Wang; Sicong Ma; Xingxing Qi; Xiaoyin Tang; Dan Cui; Zhi Wang; Jiachang Chi; Ping Li; Bo Zhai
Journal:  Mol Med Rep       Date:  2017-01-26       Impact factor: 2.952

4.  TNFRSF12A and a new prognostic model identified from methylation combined with expression profiles to predict overall survival in hepatocellular carcinoma.

Authors:  Yu Fang; Lin Xiang; La-Mei Chen; Wei-Juan Sun; Yu-Jia Zhai; Yu-Chen Fan; Kai Wang
Journal:  Transl Cancer Res       Date:  2020-09       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.